Seeking Alpha

Seeking Alpha Portfolio App for iPad

2,248 people get COV articles and Market Currents by email alert.

Get email alerts on COV »

COV

Covidien plc

6/19/2013, 2:50 AM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Monday, June 17, 7:39 AM Covidien (COV) publishes the final results of the pivotal trial for its Pipeline embolization device for the treatment of patients with an unruptured large or giant wide-necked aneurysm in Radiology, the official peer-reviewed journal of the Radiological Society. Data from this trial led the FDA to approve the treatment in 2011. (PR) Comment! [Healthcare]
Friday, May 24, 7:30 AM Some details for Covidien's (COV) pharmaceuticals business spin-off (previous): Shareholders will receive one share of the new publicly traded company (Mallinckrodt) for every eight shares of COV they own. Mallinckrodt is expected to begin trading on the NYSE on July 1 (ticker: MNK). (PR) 3 Comments [Healthcare]
Monday, May 20, 2:17 PM Covidien (COV -0.1%) says its Nellcor pulse oximetry portfolio has received FDA 501(k) clearance for motion claims. COV is the first company of its kind to receive the FDA stamp of approval for a motion-tolerant bedside device that's also compliant with the International Organization for Standardization standards for pulse oximetry. Comment! [Healthcare]
Friday, May 3, 5:17 PM Covidien (COV) reduces its FY13 net sales guidance and adjusts its financial statements for the past three years to refect the impending spinoff of its Malinckrodt business. The company now estimates that net sales in FY13 will be up 4% to 5%, which corresponds to about $12.32B to $12.44B, down from its prior projection of 5% to 8% growth. It expects Mallinckrodt to see sales growth of between 7% to 11% for the fiscal year ending September 27. Shares -0.5% AH. Comment! [Global & FX, Healthcare, Earnings]
Friday, April 26, 6:01 AM Covidien (COV): FQ2 EPS of $1.12 beats by $0.03. Revenue of $3.10B (+5% Y/Y) misses by $0.02B. (PR) Comment! [Earnings, Breaking News, Healthcare]
Friday, April 26, 12:05 AM Notable earnings before Friday’s open: ABBV, AEP, AON, ARLP, B, BKW, BPO, COV, CVX, DHI, DLR, DTE, FLIR, GDI, GNC, GT, HMSY, IMGN, ITRI, LAZ, LYB, MPW, NOV, SPG, TRP, TYC, VFC, VTR, WETF, WY Comment! [Earnings]
Thursday, April 25, 5:30 PM Notable earnings before Friday’s open: ABBV, AEP, AON, ARLP, B, BKW, BPO, COV, CVX, DHI, DLR, DTE, FLIR, GDI, GNC, GT, HMSY, IMGN, ITRI, LAZ, LYB, MPW, NOV, SPG, TRP, TYC, VFC, VTR, WETF, WY Comment! [Earnings]
Thursday, April 11, 12:37 PM Covidien (COV +1.1%) says it's entered into an agreement with VIDA Diagnostics to distribute it's Apollo pulmonary imaging software services. The agreement enables COV to offer a combination of technologies from VIDA and Covidien's i-Logic lung navigation system, which provides physicians with enhanced detail for the minimally invasive diagnosis and treatment planning of a variety of lung diseases. Comment! [Healthcare, Global & FX, On the Move]
Monday, April 1, 9:09 AM Medical products maker Covidien (COV) says it was awarded $176M as a federal court ruled several patents were infringed by Johnson & Johnson's (JNJ) Ethicon Endo-Surgery unit and its Harmonic line of ultrasonic surgical products. Comment! [Healthcare]
Thursday, March 28, 3:47 PM At least five state legislatures are considering bills to tighten oversight of methadone clinics after allegations that take-home doses of the drug are contributing to illegal street sales, misuse and deaths. The measures, if passed, could increase costs or limit revenue for the nation’s largest methadone chains - both of them backed by private equity firms: CRC Health, owned by Bain; and Colonial Management Group, which is in the portfolio of Warwick Group. 1 Comment [Healthcare]
Thursday, March 21, 9:19 AM Covidien plc (COV) declares $0.26/share quarterly dividend, in line with previous. Forward yield 1.59%. For shareholders of record Apr. 04. Payable May 03. Ex-div date Apr. 02. (PR) Comment! [Dividends]
Thursday, March 21, 7:11 AM Covidien (COV) announces a new $3B share repurchase program. The buyback comes on top of a $2B share repurchase program which still has $425M outstanding on it. Comment! [Healthcare]
Tuesday, February 5, 8:35 AM Covidien's (COV) pharmaceuticals business, which it's spinning off under the name Mallinckrodt, will apply to list its shares on the NYSE and will trade with the ticker symbol MNK. Covidien expects to complete the process in the middle of the year. Mallinckrodt generated sales of $2B in 2012. (PR) 1 Comment [Healthcare]
Friday, January 25, 2:04 PM Covidien (COV +0.4%) gives back much of its early morning pop after its FQ1 beat expectations across the board. Net profit actually declined 0.2% Y/Y however as costs to split the health-care products company masked improving sales. Sales in its medical-devices business, its largest by revenue, rose 7.6% to $ 2.13B. Medical-supplies sales increased 2.4% to $434M, while pharmaceuticals sales declined 0.2% to $489M. It also ups FY13 guidance, now seeing revenue growth of 5% to 8%, which is 2 percentage points above prior guidance. Comment! [Healthcare, Earnings]
Friday, January 25, 6:01 AM Covidien (COV): FQ1 EPS of $1.1 beats by $0.04. Revenue of $3.06B (+5% Y/Y) beats by $0.06B. (PR) Comment! [Earnings, Healthcare, Breaking News]
Friday, January 25, 12:05 AM Notable earnings before Friday’s open: AEP, COV, HAL, HON, IMGN, KMB, OSK, PG, WY Comment! [Earnings]